Armstrong Advisory Group’s AstraZeneca AZN Stock Holding History

Armstrong Advisory Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136K	Hold	715	–	–	0.01%	312
2026 Q1	$141K	Sell	715 -1	-0.1%	-$193	0.01%	274
2025 Q4	$132K	Hold	716	–	–	0.01%	273
2025 Q3	$110K	Hold	716	–	–	0.01%	291
2025 Q2	$100K	Buy	716 +6	+0.8%	+$841	0.01%	287
2025 Q1	$93K	Hold	710	–	–	0.01%	282
2024 Q4	$93K	Hold	710	–	–	0.01%	282
2024 Q3	$111K	Sell	710 -21	-3%	-$3.39K	0.01%	262
2024 Q2	$114K	Buy	731 +21	+3%	+$3.16K	0.01%	241
2024 Q1	$95.6K	Hold	710	–	–	0.01%	258
2023 Q4	$95.6K	Hold	710	–	–	0.01%	258
2023 Q3	$96.1K	Buy	710 +50	+8%	+$6.83K	0.01%	243
2023 Q2	$94.4K	Hold	660	–	–	0.01%	248
2023 Q1	$91.6K	Hold	660	–	–	0.01%	248
2022 Q4	$89.4K	Buy	+660	New	+$82.8K	0.01%	248

Other funds holding AZN

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

CAM

Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return

MBI

Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return

SAM

Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return

Armstrong Advisory Group's AZN Position: Q2 2026 in Review

Armstrong Advisory Group held its AstraZeneca (AZN) position steady in Q2 2026 at 715 shares worth $136K. The position accounts for 0.01% of the portfolio, ranked #312.

Armstrong Advisory Group first reported a position in AZN in Q4 2022 and has held it in 15 quarters since. The position peaked at $141K in Q1 2026. 309 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Armstrong Advisory Group held 715 shares of AstraZeneca worth $136K as of Q2 2026.
Armstrong Advisory Group left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #312 holding.
Armstrong Advisory Group first reported a position in AstraZeneca in Q4 2022 and has held it in 15 quarters since.
Armstrong Advisory Group's AstraZeneca position peaked at $141K in Q1 2026.
309 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.